Explore federal awards
Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
Export these results to CSV · 11 matching records
PRE-CLINICAL MODELS OF INFECTIOUS DISEASESDepartment of Health and Human Services$496.8K obligationsEnds Sep 23, 2026
BIOMATERIAL PROTEIN AND FIBER DEVELOPMENT (BRDL)Department of Defense$325.0K obligationsEnds Nov 30, 2026
COMPREHENSIVE IN VITRO ANTIVIRAL SCREENING AGAINST VIRUSES OF PANDEMIC POTENTIAL UNDER ANTIVIRAL PROGRAM FOR PANDEMICS (APP)Department of Health and Human Services$2.0M obligationsEnds Dec 31, 2026
MUDDY CREEK FOCAL AREA ASPEN GENETICSDepartment of the Interior$89.4K obligationsEnds Sep 30, 2026
B27 - IN VITRO SCREENING MPOX AND ECTROMELIA VIRUSESDepartment of Health and Human Services$66.3K obligationsEnds Jan 14, 2027
IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY AGAINST RESPIRATORY VIRUSESDepartment of Health and Human Services$456.0K obligationsEnds Jun 14, 2024
TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT USING ASSAYS SUCH AS CPE TO DETERMINE EC50; ASSAYS SUCH AS VYR/PR TO DETERMINE EC90, AND CYTOTOXICITY (CC50) OF EXPERIMENTAL…Department of Health and Human Services$418.9K obligationsEnds Jan 8, 2027
RESEARCH AND DEVELOPMENT - LABOR (BY)Department of Defense$661.9K obligationsEnds Mar 12, 2026
COMPREHENSIVE VIRAL SCREENING PANEL.Department of Health and Human Services$372.9K obligationsEnds Dec 15, 2025
IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY AGAINST RESPIRATORY VIRUSESDepartment of Health and Human Services$229.5K obligationsEnds Sep 22, 2025
TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT AND CYTOTOXICITY OF EXPERIMENTAL ANTIVIRAL COMPOUNDS AGAINST VIRUSES LISTED IN GROUPS 4, 5, 6, AND 7, AS WELL AS OTHER RAPIDLY…Department of Health and Human Services$618.5K obligationsEnds Sep 20, 2021